Literature DB >> 9851669

Expression of insulin-like growth factor binding protein 1-6 genes in adrenocortical tumors and pheochromocytomas.

V Ilvesmäki1, J Liu, P Heikkilä, A I Kahri, R Voutilainen.   

Abstract

The insulin-like growth factor (IGF) system appears to be important in the regulation of adrenal growth and hormone synthesis. As IGF-binding proteins (IGFBPs) modify IGF bioactivity, we investigated the expression of IGFBP 1-6 genes in different adrenal tumors and hyperplasias to further clarify the role of the IGF system in adrenal pathophysiology. IGFBP-1 mRNA levels were too low to be detected by Northern blot analysis, but could be found by RT-PCR in some tumors and hyperplastic adrenals. Other IGFBPs were detected by Northern blotting. IGFBP-3 mRNA levels were very low in normal adrenals. In adrenal tumors and hyperplastic adrenals, IGFBP-3 mRNA expression was usually higher than in normal adrenals. In hormonally active adrenocortical carcinomas, IGFBP-2, -4, -5 and -6 mRNA levels were lower than in nonfunctional carcinomas and normal adrenals. The low IGFBP mRNA expression in the hormone-producing carcinomas was associated with high IGF-II mRNA content. In adrenocortical adenomas from patients with Cushing's or Conn's syndrome, mean IGFBP mRNA levels were higher than in normal adrenals or in hormonally inactive adenomas. In nodular and bilateral hyperplasias, IGFBP-2, -3 and -4 mRNA expression was on average higher than in normal adrenals but varied substantially, as did IGFBP mRNA levels in pheochromocytomas. In comparison to normal adrenals, pheochromocytomas expressed on average higher levels of IGFBP-2 and -4 but less IGFBP-5 and -6 mRNAs. Our data show that the six IGFBPs 1-6 are expressed at variable level in adrenal tumors and hyperplasias. The low level of IGFBP mRNAs in hormonally active adrenocortical carcinomas was of particular interest.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9851669     DOI: 10.1055/s-2007-978945

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  8 in total

Review 1.  A diagnostic approach to adrenal cortical lesions.

Authors:  Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

2.  Elucidating the Role of the Maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma.

Authors:  Katja Kiseljak-Vassiliades; Yu Zhang; Adwitiya Kar; Raud Razzaghi; Mei Xu; Katherine Gowan; Christopher D Raeburn; Maria Albuja-Cruz; Kenneth L Jones; Hilary Somerset; Lauren Fishbein; Stephen Leong; Margaret E Wierman
Journal:  Endocrinology       Date:  2018-07-01       Impact factor: 4.736

3.  Hepatic leptin signalling and subdiaphragmatic vagal efferents are not required for leptin-induced increases of plasma IGF binding protein-2 (IGFBP-2) in ob/ob mice.

Authors:  J Levi; F K Huynh; H C Denroche; U H Neumann; M M Glavas; S D Covey; T J Kieffer
Journal:  Diabetologia       Date:  2011-12-28       Impact factor: 10.122

4.  Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase.

Authors:  C M Simbulan-Rosenthal; D H Ly; D S Rosenthal; G Konopka; R Luo; Z Q Wang; P G Schultz; M E Smulson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

5.  LONG-TERM FOLLOW UP AND TREATMENT OUTCOMES OF A 2 YEAR-OLD-BOY WITH METASTATIC TESTOSTERONE-SECRETING ADRENOCORTICAL CARCINOMA.

Authors:  Danielle LoGiurato; Zoltan Antal; Ping Zhou
Journal:  AACE Clin Case Rep       Date:  2020-08-06

6.  Genotype and tumor locus determine expression profile of pseudohypoxic pheochromocytomas and paragangliomas.

Authors:  Uma Shankavaram; Stephanie M J Fliedner; Abdel G Elkahloun; Jenifer J Barb; Peter J Munson; Thanh T Huynh; Joey C Matro; Hana Turkova; W Marston Linehan; Henri J Timmers; Arthur S Tischler; James F Powers; Ronald de Krijger; Bora E Baysal; Martina Takacova; Silvia Pastorekova; David Gius; Hendrik Lehnert; Kevin Camphausen; Karel Pacak
Journal:  Neoplasia       Date:  2013-04       Impact factor: 5.715

7.  IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.

Authors:  Maria Cristina De Martino; Peter M van Koetsveld; Richard A Feelders; Wouter W de Herder; Fadime Dogan; Joseph A M J L Janssen; Davine Hofste Op Bruinink; Claudia Pivonello; A Marlijn Waaijers; Annamaria Colao; Ronald R de Krijger; Rosario Pivonello; Leo J Hofland
Journal:  Endocrine       Date:  2019-03-05       Impact factor: 3.633

8.  Is there a role for the IGF system and epidermal growth factor (EGF) in the pathogenesis of adrenocortical adenomas? A preliminary case-control study.

Authors:  I Lazúrová; I Jochmanová; Š Sotak; I Špaková; M Mareková
Journal:  Physiol Res       Date:  2020-11-19       Impact factor: 1.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.